In the pharmaceutical industry, granulation plays a key role in the production of solid dosage forms – particularly due to the pressure of rising costs. Granulation aims to form coarser agglomerates from fine powder. Agglomerates may consist of fixed, dry grains, and each grain is an agglomeration of powder particles of sufficient strength. Granulates can be used directly as pharmaceuticals or can serve as an intermediate in the production of tablets or capsules.

L.B. Bohle Maschinen + Verfahren GmbH (Ennigerloh) offers a wide range of granulation solutions. The Bohle portfolio for manufacturing oral solids includes complete production systems as well as stand-alone machines. In addition, the mechanical engineering company specialist has developed and delivered a large number of containment applications for the pharmaceutical and food industries. An introduction to granulation concepts, fields of application and added value for customers is given below.

read more

We Look Forward to Welcoming You at the Following Events:

Successful start at PMEC India: Even at the first day, a huge number of prospects and customers visited the booth of L.B. Bohle to learn more about products and latest innovations.

As a technological leader, L.B. Bohle is well-known as an innovative and reliable machine builder in this fast growing pharma market.

 Topics of the current issue:

• L.B. Bohle shines with QbCOn® 1 at ACHEMA
• Three continuous processes in combined in one system - QbCon® 1 sets new standards in the pharmaceutical industry
• b.sure® 1- A new platform for all PLCs by L.B. Bohle
• ISO certification successfully renewed
• Continuous manufacturing in the pharmaceutical industry - Workshop in September 2018
• L.B. Bohle at training fair "Mach Mit"
• Customer presence with even more power: L.B. Bohle joins Propack® as new sales partner

Read the current issue

Innovativ chronicle

The 2^nd Workshop on Continuous Pharmaceutical Manufacturing was a huge success. More than 40 particpants from all over the world informed tehmselves about current trends and strategies.

Further impressions of this event.

Continuous Pharmaceutical Manufacturing: more than 40 experts from Asia, Europe, South and North America at the technical symposium.

For two days in the mid of September, Ennigerloh was the place to be for experts and users in the pharmaceutical industry doing research in the area of continuous manufacturing: They accepted the invitation of L.B. Bohle Maschinen + Verfahren GmbH to the “2^nd Continuous Pharmaceutical Manufacturing Symposium“ to discuss the processes of the future. “We are in constant exchange with scientists are at the technological forefront when it comes to continuous processes for the pharmaceutical industry," reports Tim Remmert, Managing Director.

“For pharmaceutical manufacturers, continuous manufacturing means shorter time to market, more flexible production even of small batches and highest precision and quality due to comprehensive process monitoring and control,” added Thorsten Wesselmann, Technical Director. This saves time and costs for our customers in the pharmaceutical industry. More than 40 guests from Asia, South America, North America and, last but not least, Europe exchanged views on the current state of developments and discussed future steps at the symposium. At the globally unique Technology Center the participants had the chance to get a first-hand impression of the sensor technology measurement, analysis and control technology in practical application.

read more

Download the program and agenda of our exclusive 3-day practical hands-on workshop by leading experts with industrial, academial and regulatory experience.

Program and Agenda!

Register Now!

In the pharmaceutical industry, one term is becoming increasingly important: containment. It describes the process of containing a substance within a defined space, a method that is suitable for protecting operators and the environment in case of high toxicity and product reactivity. At the same time, containment prevents dust, gases or vapours from being released into the environment and contaminating the product.
More than 60 percent of pharmaceutical products are produced as tablets, capsules, lozenges or similar solids. Especially in new products the active pharmaceutical ingredients (APIs) are becoming increasingly more potent. In some markets, the segment for high potency active pharmaceutical ingredients (HPAIs) is growing in the double-digit range, especially driven by oncology medication.

In addition to requirements set by manufacturing guidelines, it is essential that the product is safe for the machine operator and, of course, for the patient. As a result, machine manufacturers such as L.B. Bohle are faced with new challenges in all toxicity classes in which customers want to use plants and processes. In 2017, numerous customers with special specifications turned to the independent medium-sized family-owned company requesting, among other things, containment solutions for film coating applications and a dry granulation process.

read more

L.B. Bohle introduces the process tracking app b.sure^® at ACHEMA. b.sure^® is a monitoring application that keeps track of your process at all times. In comparison to other solutions on the market that operate via cloud, b.sure^® keeps the data in the company.

b.sure^® is web-based and can be opened either on the respective device or via the sent email.

Further information

This year´s ACHEMA in Frankfurt (Germany) was a huge success for the German machine builder L.B. Bohle. At the expansive booth, they shared with tablet press specialists, Korsch AG, interested parties and customers were able to find out more about current sold dosage production trends under the motto "Your Process in Mind".

QbCon^® 1 - The Exhibition Highlight

As the highlight of the trade fair, L.B. Bohle focused on QbCon® 1, the market's first continuous twin-screw granulator with an integrated, truly continuous dryer. The trade show visitors were enthusiastic about this unique new machine, because QbCon® 1 accomplishes truly continuous drying and granulation with very narrow and reproducible dwell times in the dryer, as well as stable quality of the granules in terms of moisture and particle size for the very first time.
By using PAT, the production process can be tracked inline. This leads to constant production of high-quality products, high patient safety, lower costs, a better process understanding and optimized process control. Complete control and monitoring of the entire process takes place via a touch panel. QbCon® 1 requires little space and is suitable for the lowest throughputs (nominal throughput: 0.5-2.5 kg / h), but throughput can be increased far greater depending on the product.
Just from seeing QbCon® 1 at the fair, customers have already arranged to get a closer look and test this machine at the Bohle facility.

This year´s ACHEMA in Frankfurt (Germany) was a huge success for the German machine builder L.B. Bohle. At the expansive booth, they shared with tablet press specialists, Korsch AG, interested parties and customers were able to find out more about current sold dosage production trends under the motto "Your Process in Mind".

read more